MVA-NSmut

BIOLOGICAL4 trials

Sponsors

ReiThera Srl, National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford

Conditions

HIV InfectionHepatitis CHepatitis C Infection

Phase 1

Study of a New MVA Vaccine for Hepatitis C Virus

CompletedNCT01296451

ReiThera SrlHepatitis C Infection

Start: 2010-12-31End: 2016-01-31Updated: 2016-04-26

Staged Phase I/II Hepatitis C Prophylactic Vaccine

CompletedNCT01436357

National Institute of Allergy and Infectious Diseases (NIAID)Hepatitis C

Start: 2012-03-06End: 2018-05-25Updated: 2019-11-19

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination

CompletedNCT02362217

University of OxfordHepatitis C Infection, HIV Infection

Start: 2014-10-31End: 2017-10-31Updated: 2018-10-11

A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals

CompletedNCT02568332

University of OxfordHepatitis C Infection

Start: 2015-07-21End: 2017-10-31Updated: 2018-10-11

Related Papers

Randomized Trial of a Vaccine Regimen to Prevent Chronic HCV Infection

New England Journal of Medicine2021-02-10159 citations

LB10. A Randomized, Double-Blind, Placebo-Controlled Efficacy Trial of a Vaccine to Prevent Chronic Hepatitis C Virus Infection in an at-Risk Population

Open Forum Infectious Diseases2019-10-0113 citations

A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection

Frontiers in Immunology2019-01-1837 citations